Literature DB >> 29246644

Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.

Fei Hu1, Yu Zhao1, Yi Yu1, Jue-Min Fang1, Ran Cui1, Zhu-Qing Liu1, Xian-Ling Guo2, Qing Xu3.   

Abstract

Signal transducer and activator of transcription (STAT)3 expression is correlated with neoplasm growth, metastasis, and prognosis; it has also been implicated in the regulation of autophagy, which may in turn contribute to tumor chemoresistance. However, it is unknown whether STAT3 is involved in cancer cell survival in response to chemotherapy. In this study, we show that autophagy is triggered during chemotherapy and that inhibiting autophagy increased chemosensitivity of castration-resistant prostate cancer (CRPC) cells. Meanwhile, docetaxel induced autophagy was inhibited by STAT3 activation, which increased mitochondrial damage and decreased CRPC cell viability. These results suggest that STAT3 contributes to CRPC cell survival and chemoresistance by modulating autophagy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy; Castration-resistant prostate cancer; Chemotherapy; STAT3

Mesh:

Substances:

Year:  2017        PMID: 29246644     DOI: 10.1016/j.canlet.2017.12.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer.

Authors:  Alan P Lombard; Allen C Gao
Journal:  Curr Opin Endocr Metab Res       Date:  2020-02-19

2.  A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.

Authors:  Jacqueline Olender; Bi-Dar Wang; Travers Ching; Lana X Garmire; Kaitlin Garofano; Youngmi Ji; Tessa Knox; Patricia Latham; Kenneth Nguyen; Johng Rhim; Norman H Lee
Journal:  Mol Cancer Res       Date:  2019-07-02       Impact factor: 5.852

Review 3.  Molecular modulation of autophagy: New venture to target resistant cancer stem cells.

Authors:  Harpreet K Mandhair; Miroslav Arambasic; Urban Novak; Ramin Radpour
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

Review 4.  Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy.

Authors:  Hong-Tao Chen; Hao Liu; Min-Jie Mao; Yuan Tan; Xiang-Qiong Mo; Xiao-Jun Meng; Meng-Ting Cao; Chu-Yu Zhong; Yan Liu; Hong Shan; Guan-Min Jiang
Journal:  Mol Cancer       Date:  2019-05-24       Impact factor: 27.401

5.  Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells.

Authors:  Xueke Wang; Xiaoyan Shao; Linaer Gu; Ke Jiang; Sitong Wang; Jianhua Chen; Juemin Fang; Xianling Guo; Min Yuan; Ji Shi; Chan Ding; Songshu Meng; Qing Xu
Journal:  J Cell Mol Med       Date:  2020-02-26       Impact factor: 5.310

6.  Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.

Authors:  Yuexiao Tang; Ke Chen; Xiaorui Luan; Jinyan Zhang; Rongrong Liu; Xiaoxiao Zheng; Shangzhi Xie; Haiping Ke; Xianning Zhang; Wei Chen
Journal:  Int J Oncol       Date:  2020-11-02       Impact factor: 5.650

7.  Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy.

Authors:  Yang Yu; Fu-Han Yang; Wen-Tao Zhang; Ya-Dong Guo; Lin Ye; Xu-Dong Yao
Journal:  Cell Biosci       Date:  2021-01-07       Impact factor: 7.133

8.  Schisandrin B synergizes docetaxel-induced restriction of growth and invasion of cervical cancer cells in vitro and in vivo.

Authors:  Chunmei Yan; Liya Gao; Xiaofei Qiu; Chunxia Deng
Journal:  Ann Transl Med       Date:  2020-09

9.  The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.

Authors:  Jiayi Li; Chaoji Shi; Rong Zhou; Yong Han; Shengming Xu; Hailong Ma; Zhiyuan Zhang
Journal:  Cancer Sci       Date:  2020-07-16       Impact factor: 6.716

10.  Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.

Authors:  Jing He; Xiao-Yan Shi; Zhi-Min Li; Xiao-Hua Pan; Ze-Lian Li; Ying Chen; Shi-Jie Yan; Lan Xiao
Journal:  BMC Mol Cell Biol       Date:  2019-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.